Enhancement of radiation sensitivity with BH3I-1 in non-small cell lung cancer

Clinical and Investigative Medicine

Volumn 28, Issue 2, 2005, Pages 55-63

  Roa, Wilson ^a   Chen, H ^a   Alexander, A ^a   Gulavita, S ^b   Th'ng, J ^b   Sun, X J ^a   Petruk, K ^a   Moore, R ^a  

^a CROSS CANCER INSTITUTE   (Canada)

^b Northwestern Ontario Regional Cancer Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 5 (4 BROMOBENZYLIDINE) ALPHA ISOPROPYL 4 OXO 2 THIOXO 3 THIOZOLIDINEACETIC ACID; ANTIMITOTIC AGENT; BH3I 1; CYTOCHROME C; MUTANT PROTEIN; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL STRAIN; CELL SURVIVAL; CLONOGENIC ASSAY; CONFOCAL MICROSCOPY; FLOW CYTOMETRY; GAMMA RADIATION; HUMAN; HUMAN CELL; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN DOMAIN; RADIATION DOSE; RADIOSENSITIVITY; WESTERN BLOTTING;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; FLOW CYTOMETRY; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; RADIATION-SENSITIZING AGENTS; THIAZOLES;

EID: 18744386936     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Pena JC, Thompson CB, Recant W, et al. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999;85:164-70
3. Oezzella F, Turley H, Kuzu I, et al: Bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 1993;329:690-4.
4. Reeve JG, Xiong J, Morgean J, Blehen NM. Expression of apoptosis-regulatory genes in lung tumor cell lines: relationship to p53 expression and relevance to acquired drug resistance. J Cancer 1996;73:193-200.
5. Reed JC, Miyashita T, Takayama S. et al. Bcl-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996;60:23-32.
6. DiPaola RS, Aisner J. Overcoming Bcl-2- and p53-mediated resistance in prostate cancer. Semin Oncol 1999;26:112-6.
7. Adams JM, Cory S. Life-or-death decision by the bcl-2 protein family. Trends Biochem Sci 2001;26:61-6.
8. Antosson B, Martinou JC. The bcl-2 protein family. Exp Cell Res 2000;256:50-7.
9. Antosson B. Bax and other pro-apoptotic bcl-2 family 'killer-proteins' and their victim, the mitochondrion. Cell Tissue Res 2001;306:347-60.
10. Chi KC, Wallis AE, Lee CH. et al. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat. 2000;63:199-212.
11. Lopes de Menezes DE, Hudon N, McIntosh N. et al. Molecular and pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 2000;6:2891-902.
12. Leech SH, Olie RA, Gautschi O, Simoes-Wust P, Tschopp A, Haner S, Hall R, Stahel J, Zangemeister-Wittke RA. Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. Int J Cancer 2000;86:570-6.
13. Finneger NM, Curtin JF, Prevost G, Morgan B, Cotter TG. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br J Cancer 2001;85:115-21.
14. Holinger EP, Chittenden T, Lutz RJ. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem 1999;274:13298-304.
15. Polster BM, Kinnally KW, Fiskum G. BH3 death domain peptide induces cell type-selective mitochondrial outer membrane permeability. J Biol Chem 2001;276:37887-94.
16. Wang JL, Dongxiang L, Zhang Z-L, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000;97:7124-9.
17. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Juan J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nature Cell Biol 2001;3:173-82.
18. Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001;44:4313-24.
19. Feng WF, Liu FT, Patwari Y, Agrawal SG, Newland AC, Jia L. BH-3 domain mimetic compound BH3I-2′ induces rapid damage to the inner mitochondrial membrane prior to the cytochrome c release from mitochondria Br J Haematol 2003;21:332-40.
20. Stuschke M, Sak A, Wurm R, Sinn B, Wolf G, Stuben G, Budach V. Radiation-induced apoptosis in human non-small-cell lung cancer cell lines is secondary to cell cycle progression beyond the G2 phase checkpoint. Int J Radiat Biol 2002;78:807-9.
21. Streffer J, Rimner A, Riegere J, Naumann U, Rodemann HP, Weller M. Bcl-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neuro-Oncol 2002;56:43-9.
22. Kharbranda S, Pandey P, Schofield L, Israels S, Roncinske R, Yoshida K, Bharti A, Yuan ZM, Saxena S, Kufe D. Role of Bcl-xL as an inhibitor of cytosolic cytochrome c accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 1997;94:6939-42.
23. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Kohn KW. Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Research 1997;57:4285-300.
24. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila I, Mulshine JL, Minna JD, Gazdar AF. Oncogene 1992;7:171-80.
25. Roa WH, Chen H, Fulton D, Gulavita S, Shaw A, Th'ng J, Farr-Jones M, Moore R, Petruk K. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells. Clin Invest Med 2003;26:231-42.
26. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB, Wild-type p53 in a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-5.
27. Wu X, Levine A. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Sci USA;91:3602-6.
28. Hao J, Ming Y, Feng-Ting L, Newland A, Jia L. Bcl-2 Inhibitors Sensitize Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Uncoupling of Mitochondrial Respiration in Human Leukemic CEM Cells. Cancer Research 2004;63:3607-16.
29. Lewe SW, Schmitt EM, Smith SW, Osborne B, Jack T. Nature 1993;847-9.
30. Haas-Kogan DA, Yount G, Haas M, Levi D, Kogan SS, Hu L, Vidair C, Deen DF, Dewey WC, Israel MA. P53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Int J Radiat Oncol Biol Phys 1996;36:95-103.
31. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-9.
32. Lee JM, Berstein A. P53 mutation increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993;90:5742-6.